GeoVax Labs (GOVX) Stock Price, News & Analysis

Company Overview

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research programs are based primarily on modified vaccinia Ankara (MVA) and virus-like particle technologies, which are designed to stimulate broad and durable immune responses.

GeoVax’s pipeline has included GEO-CM04S1, an investigational COVID-19 vaccine candidate intended to generate immune responses against multiple viral components, as well as vaccine programs targeting HIV. The company is also researching immunotherapies and vaccine-based approaches for selected cancers and other infectious diseases.

Based in Atlanta, Georgia, GeoVax has conducted development activities and clinical research through collaborations with government agencies, academic institutions and other research organizations. Its products remain investigational and are subject to clinical testing and regulatory review before they can be marketed.

Key Stats

• Today's Range: $0.35 to $0.37
• 50-Day Range: $0.36 to $1.05
• 52-Week Range: $0.35 to $17.50
• Volume: 289,123 shs
• Average Volume: 644,029 shs
• Market Capitalization: $2.64 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $150.00
• Consensus Rating: Hold

GeoVax Labs Stock Analysis - MarketRank™

GeoVax Labs scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

GeoVax Labs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

GeoVax Labs has a consensus price target of $150.00, representing about 41,717.7% upside from its current price of $0.36.

Amount of Analyst Coverage

GeoVax Labs has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for GeoVax Labs are expected to grow in the coming year, from ($4.94) to ($2.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GeoVax Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GeoVax Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GeoVax Labs has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.02% of the float of GeoVax Labs has been sold short.

Short Interest Ratio / Days to Cover

GeoVax Labs has a short interest ratio ("days to cover") of 0.18, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GeoVax Labs has recently increased by 101.56%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GeoVax Labs does not currently pay a dividend.

Dividend Growth

GeoVax Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.47

News Sentiment

GeoVax Labs has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for GeoVax Labs this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for GOVX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

3 people have added GeoVax Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GeoVax Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.22% of the stock of GeoVax Labs is held by insiders.

Percentage Held by Institutions

6.09% of the stock of GeoVax Labs is held by institutions.

Company Calendar

• Last Earnings: 7/27/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GOVX
• CIK: 832489
• Web: www.geovax.com
• Phone: (678) 384-7220
• Fax: 678-384-7281
• Employees: 19
• Year Founded: 2001

Price Target and Rating

• Average Price Target for GeoVax Labs: $150.00
• High Price Target: $150.00
• Low Price Target: $150.00
• Potential Upside/Downside: +41,717.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($11.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.47 million
• Net Margins: N/A
• Pretax Margin: -2,508.10%
• Return on Equity: -743.64%
• Return on Assets: -394.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.54
• Quick Ratio: 1.54

Sales & Book Value

• Annual Sales: $2.49 million
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.21 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 7,370,000
• Free Float: 7,353,000
• Market Cap: $2.64 million
• Optionable: Not Optionable
• Beta: 3.66